Press release
Endometrial Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)
Endometrial Cancer Pipeline
Key Takeaways from the Endometrial Cancer Pipeline Report
• DelveInsight's Endometrial Cancer pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Endometrial Cancer treatment.
• The leading Endometrial Cancer Companies working in the market include Merck & Co, ImmunoGen, Mersana Therapeutics, Volastra Therapeutics, Inc., BeiGene/Jazz Pharmaceuticals, Iconic Therapeutics, AstraZeneca/Daiichi Sankyo, Apollomics, Tempest Therapeutics, Totus Medicines, TORL Biotherapeutics, Tango Therapeutics, Thera technologies, Synthon, Klus Pharma, Seagen, Karyopharm Therapeutics, Inspirna, Chimerix, and others.
• Promising Endometrial Cancer Therapies in the various stages of development include TSR-042, Sacituzumab Govitecan, Olaparib, Ataluren + Pembrolizumab, Fulvestrant, and others.
• May 2024:- Karyopharm Therapeutics Inc- A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma. The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v 1.1]) after completing at least 12 weeks of platinum-based therapy.
• May 2024:- Merck Sharp & Dohme LLC- A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095).
• May 2024:- Kartos Therapeutics Inc.- A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects With TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy. The study will be conducted in 2 parts. Part 1 will evaluate safety and efficacy of two different doses of navtemadlin alongside an observational control arm to determine the Phase 3 navtemadlin dose. Part 2 will evaluate the efficacy and safety of navtemadlin Phase 3 dose compared to placebo.
Request a sample and discover the recent advances in Endometrial Cancer @ Endometrial Cancer Pipeline Outlook Report- https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Endometrial Cancer Overview
Endometrial cancer is cancer of the endometrium, which is the lining of the uterus. It is the most common type of cancer that affects the female reproductive organs. The most common type of endometrial cancer (type 1) grows slowly. It most often is found only inside the uterus. Type 2 is less common. It grows more rapidly and tends to spread to other parts of the body. Endometrial cancer occurs when the cells of the endometrium start to grow too rapidly.
The lining of the uterus may thicken in certain places. These areas of thickness may form a mass of tissue called a tumor. Cancer cells also can spread (metastasize) to other areas of the body. Endometrial cancer is a type of cancer that begins as a growth of cells in the uterus. The uterus is the hollow, pear-shaped pelvic organ where fetal development happens. Endometrial cancer begins in the layer of cells that form the lining of the uterus, called the endometrium. Endometrial cancer is sometimes called uterine cancer.
Endometrial Cancer Emerging Drugs Profile
• LENVIMA: Merck & Co
Lenvatinib is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. LENVIMA is being developed in combination with KEYTRUDA. LENVIMA is being developed in collaboration with Eisai. Currently, the drug is in Phase III stage of its development for the treatment of endometrial cancer.
• Mirvetuximab soravtansine: ImmunoGen
Mirvetuximab soravtansine (IMGN853) is a first-in-class ADC comprising a folate receptor alpha (FRα)-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent to kill the targeted cancer cells. Currently, the drug is in Phase II stage of its development for the treatment of endometrial cancer.
• XMT 1660: Mersana Therapeutics
XMT-1660 is a B7-H4-directed Dolasynthen ADC with a precise, target-optimized drug-to-antibody ratio (DAR 6) and a proprietary payload with controlled bystander effect. B7-H4 is overexpressed in a range of cancers, including breast, endometrial and ovarian tumors. B7-H4 (VTCN1) exerts immunosuppressive effects by suppression of T cell proliferation and is expressed on tumor-associated macrophages (TAMs) as well as epithelial tumor cells. Currently, the drug is in Phase I stage of its development for the treatment of endometrial cancer.
• VLS-1488: Volastra Therapeutics, Inc.
VLS-1488 is a potent oral KIF18A inhibitor with the potential to be the first-ever chromosomal instability-targeted cancer therapy. VLS-1488 and sovilnesib (formally AMG650) make up Volastra's innovative clinical portfolio of differentiated KIF18A inhibitors specifically designed for the treatment of solid tumors characterized by high levels of chromosomal instability (CIN). Currently, the drug is in Phase I/II stage of its development for the treatment of endometrial cancer.
Learn more about Endometrial Cancer in clinical trials @ Endometrial Cancer Drugs- https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Endometrial Cancer Therapeutics Assessment
There are approx. 50+ key companies which are developing the therapies for Endometrial Cancer. The companies which have their Endometrial Cancer drug candidates in the mid to advanced stage, i.e. Phase III include Merck & Co.
DelveInsight's Endometrial Cancer Pipeline Report covers around 50+ products under different phases of clinical development like
• Late-stage products (phase III)
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Discover more about Endometrial Cancer in development @ Endometrial Cancer Clinical Trials- https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Endometrial Cancer Companies
Merck & Co, ImmunoGen, Mersana Therapeutics, Volastra Therapeutics, Inc., BeiGene/Jazz Pharmaceuticals, Iconic Therapeutics, AstraZeneca/Daiichi Sankyo, Apollomics, Tempest Therapeutics, Totus Medicines, TORL Biotherapeutics, Tango Therapeutics, Thera technologies, Synthon, Klus Pharma, Seagen, Karyopharm Therapeutics, Inspirna, Chimerix, and others.
Endometrial Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
• Subcutaneous
• Intravenous
• Oral
• Intramuscular
• Molecule Type
Endometrial Cancer Products have been categorized under various Molecule types such as
• Small molecules
• Natural metabolites
• Monoclonal antibodies
To know more about Endometrial Cancer, visit @ Endometrial Cancer Segmentation- https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Endometrial Cancer Pipeline Report
• Coverage- Global
• Endometrial Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Endometrial Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Endometrial Cancer Companies- Merck & Co, ImmunoGen, Mersana Therapeutics, Volastra Therapeutics, Inc., BeiGene/Jazz Pharmaceuticals, Iconic Therapeutics, AstraZeneca/Daiichi Sankyo, Apollomics, Tempest Therapeutics, Totus Medicines, TORL Biotherapeutics, Tango Therapeutics, Thera technologies, Synthon, Klus Pharma, Seagen, Karyopharm Therapeutics, Inspirna, Chimerix, and others.
• Endometrial Cancer Therapies- TSR-042, Sacituzumab Govitecan, Olaparib, Ataluren + Pembrolizumab, Fulvestrant, and others.
For further information on the Endometrial Cancer Pipeline Therapeutics, reach out @ Endometrial Cancer Products Development- https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Endometrial Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Endometrial Cancer - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. LENVIMA: Merck & Co
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Mirvetuximab soravtansine: ImmunoGen
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. VLS-1488: Volastra Therapeutics, Inc.
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Endometrial Cancer Key Companies
21. Endometrial Cancer Key Products
22. Endometrial Cancer - Unmet Needs
23. Endometrial Cancer - Market Drivers and Barriers
24. Endometrial Cancer - Future Perspectives and Conclusion
25. Endometrial Cancer Analyst Views
26. Endometrial Cancer Key Companies
27. Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Endometrial Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated) here
News-ID: 3502529 • Views: …
More Releases from DelveInsight Business Research
Acromegaly Market Analysis 2034 - Clinical Trials, Market Size, Medication, Prev …
The Acromegaly market size in the 7MM (US, EU4, UK, and Japan) was approximately USD 1.3 billion in 2023, with the US contributing ~55% of the total market share. Among therapies, somatostatin analogs led the market with ~USD 300 million, followed by growth hormone antagonists at ~USD 90 million in EU4 and the UK.
Acromegaly is a rare hormonal disorder caused by excessive growth hormone (GH) production, typically due to a…
Alzheimer's Disease Competitive Landscape 2025: Clinical Trial Analysis, Therapi …
(Albany, USA) DelveInsight's latest report, "Alzheimer's Disease Pipeline Insight 2025", provides an in-depth and data-driven analysis of the global Alzheimer's disease (AD) clinical trial landscape, highlighting key EMA, FDA, and PDMA regulatory updates, emerging therapies, and market trends shaping the future of Alzheimer's treatment.
With 110+ active players and over 120 pipeline drugs under development, the Alzheimer's therapeutic domain continues to evolve with rapid advancements in disease-modifying treatments, biomarkers, and neuroprotective…
DARZALEX Market Set to Maintain Leadership in Multiple Myeloma Therapy with Stro …
New York, USA - DelveInsight's latest report, "DARZALEX Market Size, Forecast, and Market Insight - 2032," provides a comprehensive analysis of DARZALEX (daratumumab) market performance, competitive landscape, and future growth projections across the seven major markets (7MM): the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report offers key product insights, market dynamics, competitor analysis, regulatory milestones, and forecasted sales trends from 2019 to…
BCL-2 Inhibitors Market Analysis 2034: Competitive Landscape, EMA, PDMA, FDA App …
(Albany, USA) DelveInsight's BCL-2 Inhibitor Market Insights Report provides an in-depth analysis of current treatment practices, emerging therapies, and market trends for BCL-2 inhibitors across the 7MM (the US, EU4, the UK, and Japan) from 2020 to 2034. The report highlights that the BCL-2 inhibitors market is poised for significant growth, fueled by the rising incidence of cancer, increased awareness of these targeted therapies, and a growing pipeline of BCL-2…
More Releases for Endometrial
Rising Prevalence Of Endometrial Cancer Through Advances In The Endometrial Canc …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Endometrial Cancer Treatment Industry Market Size Be by 2025?
In recent years, the market size for endometrial cancer treatment has experienced consistent growth. It is projected to increase from $31.04 billion in 2024 to $32.09 billion in 2025, indicating a compound annual growth rate (CAGR) of…
Rising Prevalence Of Endometrial Cancer Through Advances In The Endometrial Canc …
The Endometrial Cancer Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Endometrial Cancer Treatment Market Size and Projected Growth Rate?
The Endometrial Cancer Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to…
Endometrial Biopsy Cannulae Market 2023
The report presents detailed information regarding the prominent players and potential competitors in the Endometrial Biopsy Cannulae market. It includes comprehensive insights into their worldwide presence, economic performance, strategies, upcoming product releases, research and development initiatives, and a SWOT analysis. Additionally, the report analyses revenue share and contact details for each player.
This comprehensive report aims to evaluate and forecast the market size for Fuel Monitoring Systems. It analyses revenue, growth…
Hysteroscopic Endometrial Resection Market - Transforming Hysteroscopy, Enhancin …
Newark, New Castle, USA - Growth Plus Reports has published a new report on Hysteroscopic Endometrial Resection Market, which includes a detailed analysis based on competitors and important market segments (2023-2031). The Global Hysteroscopic Endometrial Resection provides a thorough analysis of many segments such as opportunities, market size, developments, innovation, sales, and overall growth of leading players. The research is based on primary and secondary statistical data, and it includes…
Endometrial Ablation Market snapshot 2024
Global Endometrial Ablation Market: Snapshot
With the rising prevalence of gynecology disorders, such as polycystic ovarian disease (PCOD), abnormal vaginal bleeding, the global adoption of endometrial ablation procedures has increased significantly, leading to an impressive rise in the worldwide endometrial ablation market. Apart from this, the upswing in the incidence rate of cervical and endometrial cancer in women is also driving the growth of this market substantially across the world.
Download The…
Global Endometrial Ablation Market: Radiofrequency Endometrial Ablation Devices …
With the presence of large players, such as Hologic Corp., Boston Scientific Corp., Cooper Surgical Inc., Ethicon Inc., and Medtronic Plc at the global level, the worldwide market for endometrial ablation demonstrates a highly competitive landscape, finds a new research report by Transparency Market Research (TMR).
The market players are focusing aggressively on developing their offerings technologically, which is likely to lead to price differentiation, resulting in intense rivalry between these…
